Loading…
Loading…
The VanEck Biotech ETF (BBH) aims to closely reflect the price appreciation and income yield of the MVIS US Listed Biotech 25 Index (MVBBHTR), prior to the deduction of fees and expenses. This index monitors the aggregate performance of corporations involved in the research, manufacturing, promotion, and sale of medications derived from genetic insights and diagnostic technologies.
Is BBH's expense ratio expensive, average, or a steal for its category?
Pro reveals the verdict on a 5-tier spectrum calibrated against ICI 2025 industry averages, with strategy-aware bands so the comparison is meaningful.
Healthcare ETFs are hovering near 52-week highs as earnings prospects improve, clinical breakthroughs advance and GLP-1 demand expands. Explore five ETFs riding the rally.
Both of these ETFs look the part, but only one is truly the better buy for investors.
For investors seeking momentum, VanEck Biotech ETF BBH is probably on the radar. The fund just hit a 52-week high and has risen 41.1% from its 52-week low price of $176.30/share.
NEW YORK--(BUSINESS WIRE)--BBH Capital Partners Private Equity (BBHCP) today announced the successful exit of its investment in The Granite Group (Granite), a diversified distributor of plumbing and HVAC products, in connection with Granite's agreement to be acquired by Watsco, Inc. (NYSE: WSO). Founded in 1971 and headquartered in Concord, New Hampshire, Granite is a third-generation, family-led distributor serving customers across New Hampshire, Vermont, Maine, Massachusetts, Connecticut, Rho.
The First Trust NYSE Arca Biotechnology Index Fund has outperformed the VanEck Biotech ETF on a one-year basis and over the last five years. The VanEck Biotech ETF offers a lower expense ratio of 0.35% compared to 0.55% for the First Trust fund.